The MedTech Funding Mandate policy is a new national priority for NHS commissioners and seeks to spread innovations that have previously been supported by the Innovation Technology Tariff /Innovation Technology Payment ITP. Initially delayed by the pandemic, it launched on the 1st April 2021.
As an AHSN, part of our role is to help the adoption and spread of these innovations across our region. The four being supported in 2021/22 are:
- Placental growth factor-based testing – a blood test to rule out pre-eclampsia in pregnant women.
- SecurAcath – for securing percutaneous catheters.
- HeartFlow – creates a 3D model of a patient’s coronary arteries and assesses the extent and location of blockages.
- GammaCore – a handheld device which alleviates the symptoms of severe cluster headaches.
As an AHSN Network, we will work closely with the Accelerated Access Collaborative (AAC), to support organisations to adopt these products and improve healthcare in our region.
Over the next few months, we will be producing a series of case studies to explore how we have supported the uptake of all four innovations in hospital trusts across Yorkshire and the Humber.